Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
3(30%)
Results Posted
0%(0 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
5
50%
Ph phase_2
2
20%
Ph phase_3
1
10%

Phase Distribution

5

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Active, not recruiting2
unknown1
Withdrawn1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (62.5%)
Phase 22 (25.0%)
Phase 31 (12.5%)

Trials by Status

unknown110%
withdrawn110%
active_not_recruiting220%
completed440%
recruiting110%
terminated110%

Recent Activity

3 active trials
Showing 5 of 10
active_not_recruitingphase_1

ALA-induced PpIX Fluorescence During Brain Tumor Resection

NCT02191488
active_not_recruitingphase_2

PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

NCT03897491
recruitingphase_3

Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)

NCT06160492
completedphase_2

Sonodynamic Therapy with ExAblate System in Glioblastoma Patients

NCT04845919
completedphase_1

Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid

NCT04164849
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02191488Phase 1

ALA-induced PpIX Fluorescence During Brain Tumor Resection

Active Not Recruiting
NCT03897491Phase 2

PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

Active Not Recruiting
NCT06160492Phase 3

Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)

Recruiting
NCT04845919Phase 2

Sonodynamic Therapy with ExAblate System in Glioblastoma Patients

Completed
NCT04164849Phase 1

Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid

Completed
NCT04055688

Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas

Completed
NCT04390802

A Pilot Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Pituitary Adenomas

Unknown
NCT00977795Phase 1

A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors

Withdrawn
NCT00870779Phase 1

Fluorescence Guided Resection of Brain Tumors

Completed
NCT01502605Phase 1

Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10